Psoriatic Arthritis Treatment Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2028

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Psoriatic Arthritis Treatment Market, By Product

7.1. Psoriatic Arthritis Treatment Market, by Product Type, 2021-2028

7.1.1. Prescriptions

7.1.1.1. Market Revenue and Forecast (2016-2028)

7.1.2. OTC

7.1.2.1. Market Revenue and Forecast (2016-2028)

7.1.3. Others

7.1.3.1. Market Revenue and Forecast (2016-2028)

Chapter 8. Global Psoriatic Arthritis Treatment Market, By Route of Administration

8.1. Psoriatic Arthritis Treatment Market, by Route of Administration, 2021-2028

8.1.1. Topical

8.1.1.1. Market Revenue and Forecast (2016-2028)

8.1.2. Oral

8.1.2.1. Market Revenue and Forecast (2016-2028)

8.1.3. Injectable

8.1.3.1. Market Revenue and Forecast (2016-2028)

Chapter 9. Global Psoriatic Arthritis Treatment Market, By Drug Class 

9.1. Psoriatic Arthritis Treatment Market, by Drug Class, 2021-2028

9.1.1. NSAIDs

9.1.1.1. Market Revenue and Forecast (2016-2028)

9.1.2. DMARD

9.1.2.1. Market Revenue and Forecast (2016-2028)

9.1.3. Biologics

9.1.3.1. Market Revenue and Forecast (2016-2028)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2016-2028)

Chapter 10. Global Psoriatic Arthritis Treatment Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2016-2028)

10.1.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.1.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.1.4. U.S.

10.1.4.1. Market Revenue and Forecast, by Product (2016-2028)

10.1.4.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.1.4.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.1.5. Rest of North America

10.1.5.1. Market Revenue and Forecast, by Product (2016-2028)

10.1.5.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.1.5.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2016-2028)

10.2.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.2.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.2.4. UK

10.2.4.1. Market Revenue and Forecast, by Product (2016-2028)

10.2.4.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.2.4.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.2.5. Germany

10.2.5.1. Market Revenue and Forecast, by Product (2016-2028)

10.2.5.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.2.5.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.2.6. France

10.2.6.1. Market Revenue and Forecast, by Product (2016-2028)

10.2.6.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.2.6.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.2.7. Rest of Europe

10.2.7.1. Market Revenue and Forecast, by Product (2016-2028)

10.2.7.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.2.7.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2016-2028)

10.3.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.3.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.3.4. India

10.3.4.1. Market Revenue and Forecast, by Product (2016-2028)

10.3.4.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.3.4.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.3.5. China

10.3.5.1. Market Revenue and Forecast, by Product (2016-2028)

10.3.5.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.3.5.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.3.6. Japan

10.3.6.1. Market Revenue and Forecast, by Product (2016-2028)

10.3.6.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.3.6.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.3.7. Rest of APAC

10.3.7.1. Market Revenue and Forecast, by Product (2016-2028)

10.3.7.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.3.7.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2016-2028)

10.4.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.4.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.4.4. GCC

10.4.4.1. Market Revenue and Forecast, by Product (2016-2028)

10.4.4.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.4.4.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.4.5. North Africa

10.4.5.1. Market Revenue and Forecast, by Product (2016-2028)

10.4.5.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.4.5.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.4.6. South Africa

10.4.6.1. Market Revenue and Forecast, by Product (2016-2028)

10.4.6.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.4.6.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.4.7. Rest of MEA

10.4.7.1. Market Revenue and Forecast, by Product (2016-2028)

10.4.7.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.4.7.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2016-2028)

10.5.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.5.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.5.4. Brazil

10.5.4.1. Market Revenue and Forecast, by Product (2016-2028)

10.5.4.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.5.4.3. Market Revenue and Forecast, by Drug Class (2016-2028)

10.5.5. Rest of LATAM

10.5.5.1. Market Revenue and Forecast, by Product (2016-2028)

10.5.5.2. Market Revenue and Forecast, by Route of Administration (2016-2028)

10.5.5.3. Market Revenue and Forecast, by Drug Class (2016-2028)

Chapter 11. Company Profiles

11.1. AbbVie Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Amgen Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Johnson & Johnson Services, Inc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. AstraZeneca plc

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Bausch Health Companies Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Bristol-Myers Squibb Company

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Celgene Corporation

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Novartis International AG

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Eli Lilly and Company

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Pfizer, Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

11.11. UCB S.A.

11.11.1. Company Overview

11.11.2. Product Offerings

11.11.3. Financial Performance

11.11.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Report Details

  • Report Code:37062
  • Category:Healthcare
  • No. of Pages:250
  • Format:PDF/PPT/Excel
  • Published:January 2021
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers